JNJ Stock Analysis — Johnson & Johnson
Sector: Healthcare
AI Verdict
JNJ is cheap for the growth you’re getting at 18.6x forward earnings and a 42.6% EPS jump, and its entrenched healthcare moat makes those expectations more credible than most.
Competitive Moat
Johnson & Johnson owns a portfolio of patent-protected pharmaceuticals, medical devices, and consumer health brands that create high switching costs for hospitals and consumers. Its scale, regulatory expertise, and entrenched distribution channels make it hard for new entrants to displace its products.
Summary
A 42.6% jump in forward EPS growth is driving JNJ’s sharp re-rating after a 49.95% one-year return.
Where It Stands
JNJ trades at 18.6x next year's earnings versus the healthcare sector median of 22x, with an RSI of 55.9 and a trailing P/E of 26.5x after a 49.95% 1-year return.
Key Metrics
- RSI: 55.9 — Neutral
- Trailing P/E: 26.5x
- Forward P/E: 18.6x
- PEG Ratio: 0.64
- Earnings Growth: +0.4%
- Market Cap: $555.1B
- 1-Year Return: 49.95%
Analyst Consensus
20 Buy · 12 Hold · 0 Sell (32 analysts) · Target $265.00
Bull Case
You’re paying 18.6x forward earnings for 42.6% expected EPS growth, which is cheap for the growth on offer given JNJ’s patent and distribution moat.
Bear Case
If the multiple reverts to the sector median of 22x but earnings disappoint, the 49.95% 1-year gain could unwind quickly, especially with the RSI at a neutral 55.9.
Catalyst to Watch
Watch for upcoming drug trial results or regulatory decisions, as a major setback could threaten the 42.6% EPS growth narrative.